 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Brilife (IIBR-100) / Israel Institute for Biological Research
Trial completion: Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=843, Completed, Sponsor: Israel Institute for Biological Research (IIBR)
Recruiting --> Completed
- | IIBR-100 / Israel Institute for Biological Research
Journal: Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera. (Pubmed Central) - Feb 27, 2022
Taken together, we show that human sera from BriLife vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.
- ||| IIBR-100 / Israel Institute for Biological Research
Enrollment change, Head-to-Head: BRILIFE001: Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine. (clinicaltrials.gov) - Sep 13, 2021
P2b, N=20000, Not yet recruiting, Sponsor: NeuroRx, Inc.
We suggest that BriLife-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs. N=550 --> 20000
- | IIBR-100 / Israel Institute for Biological Research
New P2b trial, Head-to-Head: BRILIFE001: Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine. (clinicaltrials.gov) - Aug 4, 2021
P2b, N=550, Not yet recruiting, Sponsor: NeuroRx, Inc.
- | Brilife (IIBR-100) / Israel Institute for Biological Research
Enrollment open: Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (clinicaltrials.gov) - Nov 2, 2020
P1/2, N=1040, Recruiting, Sponsor: Israel Institute for Biological Research (IIBR)
N=550 --> 20000 Not yet recruiting --> Recruiting
- | Brilife (IIBR-100) / Israel Institute for Biological Research
New P1/2 trial: Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (clinicaltrials.gov) - Oct 28, 2020
P1/2, N=1040, Not yet recruiting, Sponsor: Israel Institute for Biological Research (IIBR)